|
Effects of weekly selinexor, bortezomib, dexamethasone (XVd) versus standard twice weekly bortezomib and dexamethasone (Vd) on RAS-mutated previously treated multiple myeloma (MM). |
|
|
Employment - Karyopharm Therapeutics |
|
|
No Relationships to Disclose |
|
|
Employment - Karyopharm Therapeutics |
|
|
Employment - Karyopharm Therapeutics |
Stock and Other Ownership Interests - Karyopharm Therapeutics |
|
|
No Relationships to Disclose |
|
|
Leadership - Caelum Biosciences |
Stock and Other Ownership Interests - Caelum Biosciences |
Consulting or Advisory Role - Abbvie/Genentech; Amgen; Caelum Biosciences; Celularity; GlaxoSmithKline; Janssen; Sanofi; Sorrento Therapeutics; Takeda |
Speakers' Bureau - Clinical Care Options/NCCN; PeerView |
Research Funding - Karyopharm Therapeutics; Sanofi |
Patents, Royalties, Other Intellectual Property - Patent 11-1F4 mAb for use in AL Amyloidosis |
Travel, Accommodations, Expenses - Janssen |
|
|
Employment - Karyopharm Therapeutics |